Symptoms of opioid withdrawal in the medium term · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
1 finding from 1 review
Serious adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
1 finding from 1 review
Adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher laxation response: patient assessment of change in bowel statusgat… compared with placebo (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone showed no clear difference in symptoms of opioid withdrawalhin the medium term compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
It is very uncertain whether naldemedine changes symptoms of opioid withdrawalein the medium termc compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with pneumonia
It is very uncertain whether osteopathic manipulative treatment (OMT) plus routine treatment changes mortality compared with placebo plus routine treatment (very low certainty).
1 finding from 1 review
Cure rate · people with pneumonia
It is very uncertain whether osteopathic manipulative treatment (OMT) plus routine treatment changes cure rate compared with placebo plus routine treatment (very low certainty).
1 finding from 1 review
Length of hospital stay · people with pneumonia
1 finding from 1 review
Duration of fever · people with pneumonia
1 finding from 1 review
Duration of total antibiotic therapy ‐ not reported · people with pneumonia
1 finding from 1 review
Duration of ICU stay ‐ not reported · people with pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found